In particular, Fu et al. showed that the use of STING agonists in combination with irradiated GM-CSF–secreting whole-cell vaccine (so-called STINGVAX) enhance the activity of tumor-specific CTLs in diverse murine tumor models [278]. This evidence concerns the gene STING1 and neoplasm.